Finance in pharma
What makes pharma finance distinctive: R&D as a risky capital allocation, patent-cliff revenue dynamics, pricing and reimbursement, and how the numbers differ from other industries.
Pharmaceutical finance runs on a distinct economic model: enormous upfront R&D spend, long development timelines, patent-driven revenue cliffs, and asymmetric risk-reward across a drug pipeline. This block applies core corporate finance to that reality, showing how valuation, capital allocation, and profitability analysis differ when a single Phase III failure can erase billions in value while an approval can create them. You will work through the financial metrics analysts and executives actually track, from R&D intensity to peak sales projections, benchmarked against US and European industry norms. The block closes with the regulatory and risk framework, including pricing controls, IP litigation exposure, and the due-diligence checks needed before financing, licensing, or acquiring pharmaceutical assets.
What you'll master
- Build and interpret a pipeline valuation using risk-adjusted NPV across clinical phases
- Calculate and benchmark sector-specific ratios like R&D-to-sales, gross margin, and patent cliff exposure
- Assess the financial impact of pricing regulation and reimbursement systems on projected revenues across US and EU markets
- Conduct a financial due-diligence review of a licensing deal or M&A target, flagging IP, regulatory, and litigation risks
Key terms
Modules
Covers how drug economics, patents, and revenue cycles make pharma finance distinct.
Covers the core calculations, multiples, and benchmarks used to analyse pharma companies and deals.
Covers regulatory reporting, pricing and litigation risks, and financial due diligence checks.
Latest articles
Recent articles from the blog that apply to Pharmaceuticals.
- Pharma partnership terms that protect your pipeline when the science goes sidewaysMilestone-based deals are how most biotech companies survive long enough to see their drug approved, but poorly structured agreements can leave a CFO holding the downside while the partner captures the upside. This playbook shows how to build deal terms that align incentives across a decade-long development arc.
- Risk-adjusted NPV for pre-revenue biotech pipelines: how the math actually worksMost valuation frameworks break down when applied to a drug candidate that has never generated a dollar of revenue and may never reach patients. Risk-adjusted NPV fixes that problem, but only if you understand what the model is actually doing and where it quietly fails.